Biomm Past Earnings Performance
Past criteria checks 0/6
Biomm's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 28.9% per year.
Key information
-7.6%
Earnings growth rate
4.9%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 28.9% |
| Return on equity | -25.2% |
| Net Margin | -59.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Biomm S.A. (BVMF:BIOM3) Investors Are Less Pessimistic Than Expected
Jul 05
Is Biomm (BVMF:BIOM3) Weighed On By Its Debt Load?
May 24Biomm S.A.'s (BVMF:BIOM3) 69% Price Boost Is Out Of Tune With Revenues
Apr 18Biomm S.A.'s (BVMF:BIOM3) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Nov 12We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Jul 25Positive Sentiment Still Eludes Biomm S.A. (BVMF:BIOM3) Following 26% Share Price Slump
Apr 17Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Feb 28Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Oct 15Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt
Jun 29We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Aug 17Here's Why Biomm (BVMF:BIOM3) Can Afford Some Debt
Apr 05Biomm (BVMF:BIOM3) Shareholders Have Enjoyed An Impressive 173% Share Price Gain
Mar 01Do Institutions Own Biomm S.A. (BVMF:BIOM3) Shares?
Jan 25Is Biomm (BVMF:BIOM3) A Risky Investment?
Dec 21Revenue & Expenses Breakdown
How Biomm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 123 | -73 | 94 | 0 |
| 30 Jun 24 | 124 | -78 | 101 | 0 |
| 31 Mar 24 | 122 | -80 | 97 | 0 |
| 31 Dec 23 | 118 | -81 | 92 | 0 |
| 30 Sep 23 | 125 | -82 | 93 | 0 |
| 30 Jun 23 | 122 | -86 | 88 | 0 |
| 31 Mar 23 | 114 | -90 | 86 | 0 |
| 31 Dec 22 | 105 | -93 | 90 | 0 |
| 30 Sep 22 | 101 | -101 | 96 | 0 |
| 30 Jun 22 | 107 | -92 | 97 | 0 |
| 31 Mar 22 | 119 | -82 | 97 | 0 |
| 31 Dec 21 | 107 | -80 | 90 | 0 |
| 30 Sep 21 | 104 | -74 | 87 | 0 |
| 30 Jun 21 | 86 | -70 | 79 | 0 |
| 31 Mar 21 | 63 | -71 | 71 | 0 |
| 31 Dec 20 | 59 | -71 | 68 | 0 |
| 30 Sep 20 | 44 | -58 | 54 | 0 |
| 30 Jun 20 | 26 | -60 | 51 | 0 |
| 31 Mar 20 | 16 | -60 | 50 | 0 |
| 31 Dec 19 | 9 | -56 | 47 | 0 |
| 30 Sep 19 | 5 | -55 | 43 | 0 |
| 30 Jun 19 | 5 | -51 | 39 | 0 |
| 31 Mar 19 | 3 | -48 | 34 | 0 |
| 31 Dec 18 | 2 | -43 | 31 | 0 |
| 30 Sep 18 | 1 | -38 | 31 | 0 |
| 30 Jun 18 | 0 | -38 | 30 | 0 |
| 31 Mar 18 | 0 | -38 | 30 | 0 |
| 31 Dec 17 | 0 | -38 | 31 | 0 |
| 30 Sep 17 | 0 | -42 | 28 | 0 |
| 30 Jun 17 | 0 | -41 | 29 | 0 |
| 31 Mar 17 | 0 | -45 | 27 | 0 |
| 31 Dec 16 | 0 | -46 | 26 | 0 |
| 30 Sep 16 | 0 | -32 | 27 | 0 |
| 30 Jun 16 | 0 | -14 | 24 | 0 |
| 31 Mar 16 | 0 | -5 | 22 | 0 |
| 31 Dec 15 | 0 | 8 | 20 | 0 |
| 30 Sep 15 | 0 | 4 | 19 | 0 |
| 30 Jun 15 | 0 | -5 | 18 | 0 |
| 31 Mar 15 | 0 | -5 | 17 | 0 |
| 31 Dec 14 | 0 | -13 | 16 | 0 |
| 30 Sep 14 | 0 | -13 | 15 | 0 |
| 30 Jun 14 | 0 | -15 | 12 | 0 |
| 31 Mar 14 | 0 | -14 | 11 | 0 |
Quality Earnings: BIOM3 is currently unprofitable.
Growing Profit Margin: BIOM3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOM3 is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare BIOM3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOM3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: BIOM3 has a negative Return on Equity (-25.21%), as it is currently unprofitable.